01:43 AM EDT, 09/01/2026 (MT Newswires) -- Novartis (NOVN.SW) said Tuesday that its remibrutinib medication was better than teriflunomide at reducing annualized relapse rate and inflammatory brain lesions in two phase III trials of adults with relapsing multiple sclerosis. With a favorable safety profile, remibrutinib exhibited a clinically meaningful decline versus teriflunomide in key secondary endpoints related to disability progression. In a preplanned combined analysis of REMODEL-1/-2 trials, the trend in the three-month confirmed disability progression was positive, with a nominal significance in the six-month confirmed disability progression. The innovative medicines company aims to obtain global regulatory clearance for remibrutinib in relapsing multiple sclerosis.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.